News and Press Releases

Contact Veristat Now


Request A Proposal

Contact Us

Veristat Supports Antibe Therapeutics for Pain and Inflammation Study

November 7, 2018

Upon receiving approval from Health Canada, Antibe Therapeutics selected Veristat to immediately begin work on part one of a Phase 2B dose-ranging, efficacy study for their lead drug candidate ATB-346.   The study will run in Canada and is expected to conclude in December 2018.

Read More

Veristat Strengthens Clinical Operations Capabilities - Acquires Topstone Research

October 1, 2018

Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized Biopharma

Read More

Veristat is Recognized on the Inc. 5000 List of America’s Fastest-Growing Private Companies for the 4th Consecutive Year

August 15, 2018

 Veristat’s Continued Innovation of Its Clinical Development Strategies and Services Allow the Company to Execute High Quality Trials That Reach Regulatory Approval

 

SOUTHBOROUGH, MA –  August 15, 2018 –   Veristat, a full service Clinical Research Organization (CRO), proudly announces its recognition once again by Inc. Magazine as one of the 5000 fastest-growing private companies in the United States. 

Read More